Milestone Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Milestone Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Milestone Pharmaceuticals Inc recorded a cumulative net loss of $-84 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -58.17%.

However, within the Healthcare sector 604 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4046, from total ROA ranking in the first quarter of 2026 at 4881.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	285.93 %	214.24 %	50.41 %	6.1 %	-46.96 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-84	-68	-63	-58	-56
Return On Assets (TTM)	-58.17 %	-61.81 %	-81.29 %	-85.24 %	-83.13 %
MIST's Total Ranking	# 4046	# 4881	# 4322	# 4366	# 4328
Total Assets (TTM) in million	183	194	114	88	47
Seq. Total Assets Change	-5.72 %	70.6 %	29.41 %	85.41 %	-23.23 %
Seq. Net Income Change	-	-	-	-	-

MIST's 5 Years Annual ROA >> Back to MIST Management Effectiveness >> Compare MIST ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 269
Sector	# 605
Overall	# 3977

Return On Assets Statistics
High	Average	Low
-23.87 %	-55.1 %	-85.14 %
(Jun 30 2021)		(Sep 30 2025)

News about Milestone Pharmaceuticals Inc Return on Assets ROA

Balancing Act: Milestone Pharmaceuticals Faces Financial Challenges as Etripamil Decision Approaches,

Navigating Challenges: Milestone Pharmaceuticals Confronts Financial Struggles Amid FDA Decision for EtripamilMilestone Pharmaceuticals Inc. is currently at a critical junction, as it grapples with significant financial challenges while preparing for a pivotal decision from the U.S. Food and Drug Administration (FDA) concerning its promising drug candidate, etripamil. The drug has been under scrutiny for its potential use in treating Paroxysmal Supraventricular Tachycardia (PSVT), a condition characterized by episodes of rapid heart rate. However, the FDA s recent issuance of a Complete Response Letter (CRL) for etripamil, which primarily focused on Chemistry, Manufacturing, and Controls (CMC) issues, has raised additional concerns about the company s pathway forward. Key Facts and Financial Landscape- Complete Response Letter (CRL): The FDA, in its correspondence, did not raise any clinical issues regarding etripamil, indicating that the drug’s safety and efficacy remain intact. The primary concern revolved around CMC aspects, which usually entail manufacturing quality and consistency.

Milestone Pharmaceuticals: Navigating Challenges with Strategic Talent Acquisition Ahead of Key FDA Decision

Investigation: A Path Forward for Milestone Pharmaceuticals Amid Financial StrugglesMilestone Pharmaceuticals Inc. has recently extended an invitation to investors to discuss its corporate outlook for 2025, coinciding with pivotal developments that may chart the company’s trajectory. With a major FDA decision on the horizon—a Prescription Drug User Fee Act (PDUFA) date set for March 27, 2025, regarding its innovative CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)—the stakes for Milestone are unprecedented. However, as financial indicators paint a challenging picture, key stakeholders must grapple with how the company intends to secure a bright future.For Milestone, the figures tell a daunting story. A cumulative net loss of $43 million over the 12 months leading up to the third quarter of 2024 has resulted in a return on assets (ROA) plummeting to -49.85%. This marks a significant concern, especially when set against a landscape where 585 other companies in the healthcare sector boast better financial metrics. What s more, despite a minor uptick in overall ROA rankings from 3976 to 3766 in the most recent quarter, Milestone still finds itself struggling to regain investor confidence.

Financial Statements
Milestone Pharmaceuticals Inc 's Assets	$ 183 million	MIST's Balance sheet
Milestone Pharmaceuticals Inc 's Income	$ -29 million	Quarterly MIST's Income Statement
MIST's Income by Division		See MIST's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	50.41 %	0.36 %	1 %	-37.85 %	-20.09 %
Total Assets in million	114	75	75	74	120
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-63	-42	-60	-58	-43
Annual Return On Assets	-55.53 %	-54.99 %	-79.34 %	-78.39 %	-35.76 %

MIST's 5 Years Annual ROA >> Back to MIST Management Effectiveness >> Compare MIST ROA to its Competitors

More Return On Assets Ratios
MIST's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MIST's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MIST's Competitors
Subscribers only: Roa for Milestone Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for MIST's Customers

You may also want to know
MIST's Roi	MIST's Inventory Turnover Ratio	MIST's Growth Rates	MIST's Dividend Comparisons
	MIST's Profitability Ratios	MIST's Asset Turnover Ratio	MIST's Dividend Growth
MIST's Roe	MIST's Valuation Ratios	MIST's Financial Strength Ratios	MIST's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:38:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.